1899 Coleys Toxin 2016 PD1 Inhibition 2016 PD1 Inhibition Overview Tumor Immunology Cycle The Yin and Yang of Immune Escape Cancer Is Highly Immunosuppressive T Cells Killing a Tumor Cell ID: 689595
Download Presentation The PPT/PDF document "Essential Concepts in Harnessing the Imm..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Essential Concepts in Harnessing the Immune System in Head and Neck CancerSlide2Slide3
1899: Coley’s ToxinSlide4
2016: PD-1 InhibitionSlide5
2016: PD-1 InhibitionSlide6
OverviewSlide7
Tumor Immunology CycleSlide8
The Yin and Yang of Immune EscapeSlide9
Cancer Is Highly ImmunosuppressiveSlide10
T Cells Killing a Tumor CellSlide11
Inflamed Phenotype in HNC TILsSlide12
Inflamed/Mesenchymal Intrinsic HNC SubtypeSlide13
Clinical ActivitySlide14
Recurrent and/or Metastatic HNCSlide15
Some of the PD-1/PD-L1 and CTLA-4 Targeting Agents in DevelopmentSlide16
KEYNOTE-055: Phase 2 Trial of Pembrolizumab After ProgressionSlide17
KEYNOTE-055: ORRSlide18
EXTREME vs ImmunotherapyThe Tail at the End of the CurveSlide19
Tumor ShrinkageSlide20
Case StudySlide21
Case Study (cont)Slide22Slide23
CheckMate 141: Phase 3 Trial of Nivolumab After ProgressionSlide24
CheckMate 141: OSSlide25
How Do We Select Patients? BiomarkersSlide26
PD-L1 Expression in Head and Neck CancerSlide27
CheckMate 141: OS by Tumor PD-L1 ExpressionSlide28
Association of IFN-γ Signature and PFSSlide29
PFS and OS by IFN-γ 6-Gene
Signature ScoreSlide30
CheckMate 141: OS by p16 StatusSlide31
Adverse Effect ManagementSlide32
KEYNOTE-055: TRAEs With PembrolizumabSlide33
Overview of irAEsSlide34
The Future: Immunotherapy CombinationsSlide35
Combination TherapySlide36
Immunotherapy in the First-Line SettingSlide37
Immunotherapy in the First-Line Setting (cont)Slide38
Immunotherapy in the First-Line Setting (cont)Slide39
Making Tumors Inflamed: T-VECSlide40
Changing the Immunosuppressive ME: IDOSlide41
Ongoing and Future Clinical ConceptsSlide42
Take-Home MessagesSlide43
AbbreviationsSlide44
Abbreviations (cont)Slide45
Abbreviations (cont)Slide46
Abbreviations (cont)